首页> 外文期刊>The journal of clinical endocrinology and metabolism >Clinical and Pathological Aspects of Silent Pituitary Adenomas
【24h】

Clinical and Pathological Aspects of Silent Pituitary Adenomas

机译:垂体沉默性腺瘤的临床和病理学方面

获取原文
       

摘要

Context Silent pituitary adenomas are anterior pituitary tumors with hormone synthesis but without signs or symptoms of hormone hypersecretion. They have been increasingly recognized and represent challenging diagnostic issues. Evidence Acquisition A comprehensive literature search was performed using MEDLINE and EMBASE databases from January 2000 to March 2018 with the following key words: (i) pituitary adenoma/tumor and nonfunctioning; or (ii) pituitary adenoma/tumor and silent. All titles and abstracts of the retrieved articles were reviewed, and recent advances in the field of silent pituitary adenomas were summarized. Evidence Synthesis The clinical and biochemical picture of pituitary adenomas reflects a continuum between functional and silent adenomas. Although some adenomas are truly silent, others will show some evidence of biochemical hypersecretion or could have subtle clinical signs and, therefore, can be referred to as clinically silent or “whispering” adenomas. Silent tumors seem to be more aggressive than their secreting counterparts, with a greater recurrence rate. Transcription factors for pituitary cell lineages have been introduced into the 2017 World Health Organization guidelines: steroidogenic factor 1 staining for gonadotroph lineage; PIT1 (pituitary-specific positive transcription factor 1) for growth hormone, prolactin, and TSH lineage, and TPIT for the corticotroph lineage. Prospective studies applying these criteria will establish the value of the new classification. Conclusions A concise review of the clinical and pathological aspects of silent pituitary adenomas was conducted in view of the new World Health Organization classification of pituitary adenomas. New classifications, novel prognostics markers, and emerging imaging and therapeutic approaches need to be evaluated to better serve this unique group of patients. We present a concise review of the clinical and pathological aspects of silent pituitary adenomas in view of the new World Health Organization classification of pituitary adenomas.
机译:背景垂体沉默腺瘤是具有激素合成但无激素分泌过多体征或症状的垂体前叶肿瘤。它们已得到越来越多的认可,代表了具有挑战性的诊断问题。证据收集从2000年1月至2018年3月,使用MEDLINE和EMBASE数据库进行了全面的文献检索,关键词如下:(i)垂体腺瘤/肿瘤和无功能;或(ii)垂体腺瘤/肿瘤且无声。对检索到的文章的所有标题和摘要进行了综述,并对无声垂体腺瘤领域的最新进展进行了总结。证据综合垂体腺瘤的临床和生化图像反映了功能性和沉默性腺瘤之间的连续性。尽管某些腺瘤确实是沉默的,但其他腺瘤将显示出生化过度分泌的某些证据或可能具有微妙的临床体征,因此可以称为临床沉默或“耳语”腺瘤。沉默的肿瘤似乎比分泌的肿瘤更具侵略性,复发率更高。垂体细胞谱系的转录因子已被纳入2017年世界卫生组织指南:促性腺激素谱系的类固醇生成因子1染色; PIT1(垂体特异性正转录因子1)用于生长激素,催乳激素和TSH谱系,而TPIT用于皮质激素。应用这些标准的前瞻性研究将确定新分类的价值。结论鉴于世界卫生组织对垂体腺瘤的新分类,对沉默的垂体腺瘤的临床和病理学方面进行了简要回顾。需要评估新的分类,新颖的预后标志物以及新兴的影像学和治疗方法,以更好地为这一独特的患者群体提供服务。考虑到世界卫生组织对垂体腺瘤的新分类,我们对静息性垂体腺瘤的临床和病理学方面进行了简要回顾。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号